The National Healthcare Security Administration (NHSA) has officially unveiled the preliminary review list for the 2026 National Reimbursement Drug List (NRDL), signaling a critical juncture for the world’s second-largest pharmaceutical market. Among the hundreds of candidates, the inclusion of two ultra-expensive CAR-T cell therapies—priced at approximately 1 million yuan ($138,000) per dose—has reignited a fierce debate over the sustainability of China’s public health insurance fund.
He-Yuan Biotech’s Inaticabtagene Autoleucel and JW Therapeutics’ Relmacabtagene Autoleucel have both cleared the first hurdle for inclusion. This development is particularly noteworthy as these life-saving but prohibitively expensive treatments have historically struggled to bridge the gap between their manufacturing costs and the NHSA’s stringent budget caps. The current review marks a renewed effort by manufacturers to find a middle ground with the state payer.
A key structural shift in this year's process is the utilization of the 'Commercial Insurance Innovation Drug List' as a strategic gateway. This 'Category 5' pathway allows drugs that have already been integrated into commercial supplemental insurance schemes to qualify for NRDL consideration. It represents Beijing’s attempt to build a multi-tiered healthcare system where commercial players shoulder the burden for high-cost innovations that the basic medical insurance fund cannot yet fully absorb.
However, the path to final inclusion remains fraught with difficulty. While several city-level supplemental insurance programs, known as 'Huiminbao,' currently cover CAR-T therapies, they often exclude patients with pre-existing conditions, leaving a significant portion of the intended population without coverage. Industry insiders suggest that the move to rejoin national negotiations is a desperate bid to scale up patient access, as the commercial insurance market’s reach has proved limited.
The 2026 list is not limited to oncology; it also features a suite of high-profile global and domestic innovations. Notable entries include the world’s first dual-target ADC from Baili-Tianheng, breakthrough GLP-1 weight-loss candidates from SinoCell and Innovent, and Eli Lilly’s high-profile Alzheimer’s treatment, Donanemab. This broad spectrum of entries reflects the intensifying competition within China’s biotech sector to secure state-backed volume in exchange for price concessions.
Market reaction to the news has been swift and optimistic. On the day of the announcement, the A-share innovation drug sector saw a significant rally, with several pharmaceutical stocks hitting their daily price limits. Investors appear to be betting that the NHSA’s evolving framework—incorporating commercial insurance as a bridge—will finally provide a viable commercialization path for the high-end innovative drugs that have long weighed on corporate balance sheets.